Apr 19 2024 This Week in Cardiology

Apr 19, 2024

This week's podcast covers topics such as the TACT2 trial of chelation therapy, inter-atrial shunts for heart failure, triglyceride lowering, diltiazem, and Factor Xa anticoagulants. It discusses the lack of benefit of chelation therapy post-MI, the mixed results of interatrial shunts for HF, and the potential of triglyceride reduction. Additionally, it explores the correlation between bleeding risk and the co-administration of diltiazem and Factor Xa inhibitors.

Ask episode

Chapters

Transcript

Episode notes

Introduction

00:00 • 3min

Analysis of Chelation Therapy in Patients with Diabetes

02:43 • 3min

Analyzing Clinical Trials: Power, Overestimation, and Replication Challenges

05:55 • 4min

Innovative Shunt Trials & Drug Evaluations

09:38 • 14min

Analysis of Bleeding Risk with Co-administration of Diltiazem and Factor 10a Inhibitors

23:39 • 5min

ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. TACT 2

Chelation Therapy Provides No Benefit Post-MI

https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5

Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src=

JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238
Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/
A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003
PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655

II. Interatrial Shunts for HF

No Net HF Benefit for Interarterial Shunt Device

https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk

REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2

III. Triglyceride Lowering

Early Olezarsen Results Show 50% Reduction in Triglycerides

https://www.medscape.com/viewarticle/early-olezarsen-results-show-50-reduction-triglycerides-2024a10006oz

Is It Time to Stop Treating High Triglycerides?

https://www.medscape.com/viewarticle/990126

NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2402309

Substantial Triglyceride Reduction With Plozasiran

https://www.medscape.com/viewarticle/substantial-triglyceride-reduction-plozasiran-2024a10006wf?icd=login_success_email_match_norm

JAMA Cardiology https://jamanetwork.com/journals/jamacardiology/article-abstract/2817469

IV. Diltiazem and Factor Xa inhibitors

JAMA Vanderbilt University Paper https://jamanetwork.com/journals/jama/fullarticle/2817546

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net